Brilanestrant

DB12253InvestigationalSmall molecule

ARN-810 has been used in trials studying the basic science and treatment of Breast Cancer.

Chemical structure of Brilanestrant
Mechanism
Curator reviewed
Formula / weight
C26H20ClFN2O2 · 446.91 g/mol (avg)
Code names
GDC-0810

Resolves to

Compound
UNII9MM2R1A06RCAS1365888-06-7ChEMBLCHEMBL3581693PubChem56941241
Structure
InChIKeyBURHGPHDEVGCEZ-KJGLQBJMSA-NSMILESCC\C(=C(\C1=CC=C(\C=C\C(O)=O)C=C1)C1=CC=C2NN=CC2=C1)C1=CC=C(F)C=C1Cl
Targets
P03372ESR1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Brilanestrant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In